MTOR and colorectal carcinoma: For example, studies have shown that the mTOR pathway is abnormally activated in oxaliplatin-treated CRC cells, and in vitro experiments have confirmed that the combination of oxaliplatin and mTOR inhibitors exhibits a positive synergistic effect 53.